A 7-year-old boy is brought to the child psychiatry clinic by his mother with complaints of inattention and hyperactivity at school for the past 18 months. The teacher reports that he frequently interrupts classmates, cannot sit still during lessons, and loses his pencil and homework almost daily. At home, he is impulsive, talks excessively, and has difficulty following multi-step instructions. Physical examination is unremarkable. The child's IQ is normal (WISC-IV: 102). Hearing and vision screening are normal. There is no history of seizures, head injury, or significant medical illness. His father has a history of similar symptoms in childhood. What is the most appropriate first-line pharmacological intervention for this child?

Explanation

## Diagnosis and Management of ADHD ### Clinical Presentation This 7-year-old boy presents with the classic triad of ADHD: - **Inattention:** loses items, difficulty following instructions, forgetfulness - **Hyperactivity:** cannot sit still, excessive talking - **Impulsivity:** interrupts others, acts without thinking The symptoms are present in multiple settings (school and home), persist for >6 months, and onset is before age 12. Normal IQ and sensory screening rule out intellectual disability and sensory impairment as primary causes. Positive family history (father) supports genetic predisposition. ### First-Line Pharmacological Treatment **Key Point:** Methylphenidate (a short-acting or extended-release stimulant) is the first-line pharmacological agent for ADHD in children, supported by extensive evidence and multiple international guidelines (DSM-5, NICE, AAP). | Agent | Class | Onset | Duration | First-line? | Notes | |-------|-------|-------|----------|------------|-------| | Methylphenidate | Stimulant (amphetamine) | 30–60 min | 3–4 hrs (IR); 8–12 hrs (ER) | **Yes** | Gold standard; rapid onset; good efficacy | | Atomoxetine | Non-stimulant (NRI) | 2–4 weeks | 24 hrs | No (2nd-line) | Slower onset; useful if stimulant intolerant | | Fluoxetine | SSRI | 2–4 weeks | 24 hrs | No | For comorbid depression/anxiety, not ADHD monotherapy | | Risperidone | Atypical antipsychotic | Days | 24 hrs | No | Reserved for severe aggression/conduct problems | ### Mechanism of Methylphenidate Methylphenidate blocks the reuptake of dopamine and norepinephrine in the prefrontal cortex, enhancing attention, impulse control, and executive function. Onset is rapid (within 30–60 minutes), allowing dose titration and response monitoring within weeks. **High-Yield:** Stimulants (methylphenidate, amphetamine salts) are preferred over non-stimulants as first-line agents because they have faster onset, better-established efficacy, and more predictable dose–response relationships. **Clinical Pearl:** Before initiating stimulants, screen for cardiac risk factors (personal/family history of sudden cardiac death, arrhythmias) and obtain baseline blood pressure and heart rate. An ECG is recommended if cardiac risk is present. ### Why Not the Other Options? - **Atomoxetine:** Second-line agent; slower onset (2–4 weeks); reserved for stimulant intolerance, tic disorders, or substance abuse history. - **Fluoxetine:** SSRI; not indicated for ADHD monotherapy; used only if comorbid mood/anxiety disorder. - **Risperidone:** Antipsychotic; reserved for severe behavioral dyscontrol or comorbid psychosis; not first-line for ADHD. **Mnemonic: ADHD Pharmacotherapy Hierarchy — **SNARC**: - **S**timulants (methylphenidate, amphetamines) — 1st line - **N**on-stimulants (atomoxetine, guanfacine, clonidine) — 2nd line - **A**ntidepressants (bupropion, TCAs) — 3rd line (if comorbidity) - **R**isperidone / atypical antipsychotics — adjunctive for aggression/conduct - **C**ombination therapy — if monotherapy inadequate [cite:DSM-5 ADHD Diagnostic Criteria; Harrison 21e Ch 470]